Spots Global Cancer Trial Database for myelodysplastic syndrome (mds)
Every month we try and update this database with for myelodysplastic syndrome (mds) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment | NCT02099266 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Hodgkins Lympho... Non-Hodgkins Ly... | Administration ... | 17 Years - 70 Years | University of Kansas Medical Center | |
| Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | NCT00795548 | Myelodysplastic... Acute Myeloid L... | 5-Azacitidine | 18 Years - | Heinrich-Heine University, Duesseldorf | |
| Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies | NCT00186823 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Lymphoma, Non-H... Myelodysplastic... | Miltenyi Biotec... Stem Cell Trans... TBI, systemic c... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | NCT02212561 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Mixed Phenotype... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS) | NCT00280631 | Myelodysplastic... | Ezatiostat Hydr... | 18 Years - | Telik | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | NCT01520805 | Acute Myeloid L... Myelodysplastic... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Biology Studies of Hematologic Cancers | NCT00923442 | Acute Lymphobla... Myelodysplastic... Non-Hodgkins Ly... Acute Myelogeno... Hodgkins Lympho... | 1 Year - 75 Years | National Institutes of Health Clinical Center (CC) | ||
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| MDS-CAN: A Prospective National MDS Clinical Database and Local Tissue Bank | NCT02537990 | Myelodysplastic... | 19 Years - | Sunnybrook Health Sciences Centre | ||
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients | NCT01929408 | Acute Myeloid L... Myelodysplastic... | 18 Years - 80 Years | Fred Hutchinson Cancer Center | ||
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome | NCT01599325 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| Myelodysplasic Syndromes and Risk Factors for Infection | NCT02905552 | Myelodysplastic... Infection Risk Factors IPSS High Risk | No intervention | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | NCT01286038 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia | NCT01338337 | Myelodysplastic... | Azacitidine | 18 Years - | Asociación Andaluza de Hematología y Hemoterapia | |
| A Phase 1 Trial of ASTX030 in Patients With Myelodysplastic Syndrome | NCT04608110 | Myelodysplastic... | ASTX030 | 20 Years - | Otsuka Pharmaceutical Co., Ltd. | |
| Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS | NCT02204020 | Acute Myeloid L... Myelodysplastic... | 5-azacytidine (... | 18 Years - | University of Pittsburgh | |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies | NCT05292664 | Myelodysplastic... Myelodysplastic... Myelodysplastic... Treatment-Relat... Therapy-Related... Acute Lymphobla... Acute Lymphobla... Lymphoblastic L... Lymphoblastic L... Acute Leukemia ... Acute Leukemia ... | Venetoclax Azacitidine Cytarabine Methotrexate Hydrocortisone Leucovorin Dexamethasone Vincristine Doxorubicin Dexrazoxane Calaspargase Pe... Erwinia asparag... | 1 Year - 40 Years | Dana-Farber Cancer Institute | |
| A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome | NCT03486353 | Myelodysplastic... | FF-10501-01 Azacitidine | 18 Years - | Fujifilm Pharmaceuticals U.S.A., Inc. | |
| Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | NCT01983761 | Blood And Marro... Leukemia Lymphoma Transplantation... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Lymph... | Fludarabine, Cl... Fludarabine, Me... | 1 Year - 80 Years | Targazyme, Inc. | |
| Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | NCT01050764 | Leukemia, Acute Chronic Myeloge... Myelodysplastic... Non-Hodgkin Lym... Chronic Lymphoc... Acute Myelogeno... Acute Lymphobla... | Regulatory T-ce... Conventional T-... Melphalan Thiotepa Fludarabine Anti-thymocyte ... CliniMACS CD34 ... | - 60 Years | Stanford University | |
| Pilot Study Evaluating Safety & Efficacy of DCBT: NiCord® & UNM CBU to Patients With Hematological Malignancies | NCT01221857 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Non-Hodgkin's L... Hodgkin's Disea... | NiCord® | 8 Years - 65 Years | Gamida Cell ltd | |
| A Single-arm Safety Study of Transplantation Using Umbilical Cord Blood and Human Placental-derived Stem Cells From Partially Matched Related Donors in Persons With Certain Malignant Blood Diseases and Non-malignant Disorders | NCT00596999 | Hematologic Mal... | UCB and HPDSC | - 55 Years | Celgene | |
| A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS) | NCT00502112 | Myelodysplastic... | lintuzumab lenalidomide | 18 Years - | Seagen Inc. | |
| Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00666497 | Acute Myeloid L... Myelodysplastic... | Azacitidine MGCD0103 MGCD0103 | 60 Years - | Mirati Therapeutics Inc. | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation | NCT00148980 | Myelodysplastic... Myelofibrosis | DBM for creatio... | 18 Years - | Hadassah Medical Organization | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases | NCT02145039 | Acute Leukemias Burkitt's Lymph... Chronic Myeloge... | Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ... | - 74 Years | Masonic Cancer Center, University of Minnesota | |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) | NCT01344707 | Advanced Hemato... | 4SC-202 | 18 Years - | 4SC AG | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | NCT02989844 | Acute Myelogeno... Myelodysplastic... | N-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | NCT02200380 | For Donors Related Donors ... For Recipients Acute Myelogeno... Acute Lymphobla... Myelodysplastic... Chronic Myeloge... Non-Hodgkins Ly... Hodgkins Diseas... Chronic Lymphoc... | CDX-301 CDX-301 and ple... | 18 Years - 70 Years | Celldex Therapeutics | |
| Serial Analysis of Chimerism in Patients With Refractory Cytopenia (RC) Transplanted With Reduced Intensity Conditioning (RIC) | NCT00682799 | Refractory Cyto... Reduced Intensi... Myelodysplastic... Hematopoietic S... | - 215 Months | University Hospital Freiburg | ||
| Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS) | NCT00700206 | Myelodysplastic... | Ezatiostat Hydr... | 18 Years - | Telik | |
| A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi Anemia | NCT03600909 | Fanconi Anemia Myelodysplastic... Acute Myelogeno... | Busulfan Fludarabine Cyclophosphamid... Anti-Thymocyte ... The CliniMACS d... G-CSF | 1 Month - | Memorial Sloan Kettering Cancer Center | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia | NCT01362036 | Myelodysplastic... | TXA127 | 18 Years - 65 Years | Tarix Pharmaceuticals | |
| Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT06419634 | Acute Myeloid L... Myelodysplastic... | BMS-986497 | 18 Years - | Bristol-Myers Squibb | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT | NCT01772953 | Acute Myeloid L... Myelodysplastic... | Treosulfan | - 21 Years | Center for International Blood and Marrow Transplant Research | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). | NCT03946670 | Myelodysplastic... | MBG453 Placebo Hypomethylating... | 18 Years - | Novartis | |
| Eltrombopag in Myelodysplastic Syndrome (MDS) Patients With Thrombocytopenia | NCT01286038 | Myelodysplastic... Thrombocytopeni... | Eltrombopag | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Preventing Stem Cell Transplant Complications With a Blood Separator Machine | NCT01866839 | MDS (Myelodyspl... Myeloproliferat... Lymphoma, Non-H... ALL (Acute B-Ly... AML (Acute Myel... | Graft Manipulat... | 2 Years - 80 Years | National Institutes of Health Clinical Center (CC) | |
| Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome | NCT01459159 | Myelodysplastic... | ezatiostat hydr... | 18 Years - | Telik | |
| Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT | NCT02989844 | Acute Myelogeno... Myelodysplastic... | N-803 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms | NCT05656248 | Myeloid Neoplas... | CPX-351 MHA Allogeneic Hema... | 1 Year - 21 Years | St. Jude Children's Research Hospital | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS | NCT04878432 | Myelodysplastic... | MBG453 Azacitidine Decitabine INQOVI (oral de... | 18 Years - 99 Years | Novartis | |
| Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome | NCT02979366 | Acute Myeloid L... Myelodysplastic... | S64315 once a w... S64315 twice a ... | 18 Years - | Servier | |
| Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS) | NCT01842646 | Myelodysplastic... Chronic Myelomo... | PF-04449913 | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants | NCT00378534 | Chronic Myeloge... Acute Myelogeno... Chronic Lymphoc... Acute Lymphobla... Myelodysplastic... | Miltenyi reagen... Fludarabine Cyclosporine Cyclophosphamid... FILGRASTIM (G-C... | 10 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | NCT00664677 | Leukemias Acute Myeloid L... Acute Lymphocyt... Adult T Cell Le... Chronic Myeloid... Chronic Lymphoc... Myelodysplastic... Chronic Myelomo... | Terameprocol (E... | 18 Years - | Erimos Pharmaceuticals | |
| Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome | NCT03173937 | Severe Aplastic... Hypo-Plastic MD... Myelodysplastic... | Omidubicel (for... Miltenyi CliniM... | 4 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Study of Azacitidine to Evaluate Safety and Effectiveness for Chinese Patients With Higher Risk Myelodysplastic Syndrome | NCT01599325 | Myelodysplastic... | Azacitidine | 18 Years - | Celgene | |
| A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants | NCT04812548 | Myelodysplastic... | sabatolimab azacitidine venetoclax | 18 Years - | Novartis | |
| CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT. | NCT02752243 | Myelodysplastic... Acute Leukemia | CIK-Cells | 0 Years - 80 Years | Johann Wolfgang Goethe University Hospital | |
| Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome | NCT04912063 | Acute Myeloid L... Myelodysplastic... | Lemzoparlimab Azacitidine Venetoclax | 18 Years - | AbbVie | |
| Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers | NCT01135329 | Lymphoma Leukemia Myelodysplastic... | Fludarabine Busulfan Cyclophosphamid... Mycophenolate M... Tacrolimus | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients | NCT02431351 | Myelodysplastic... | Selinexor | 18 Years - | Karyopharm Therapeutics Inc | |
| An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies | NCT02712905 | Solid Tumors an... | INCB059872 all-trans retin... azacitidine nivolumab | 18 Years - | Incyte Corporation | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome | NCT00270452 | Myelodysplastic... | WT1 and PR1 Pep... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| Microtransplantation to Treat Refractory or Relapsed Hematologic Malignancies in Younger Patients | NCT02433483 | Acute Myeloid L... Myelodysplastic... | Cytarabine Intrathecal Tri... HPC-A | - 21 Years | St. Jude Children's Research Hospital | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center | |
| Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood | NCT00923910 | Leukemia, Acute... Leukemia, Acute... Leukemia, Chron... Myelodysplastic... Non-Hodgkin's L... | WT1 Peptide-Pul... Donor Lymphocyt... IL-4 KLH WT1 Peptides Endotoxin Diphenhydramine Acetaminophen | 1 Year - 74 Years | National Institutes of Health Clinical Center (CC) | |
| Study of INCB053914 in Subjects With Advanced Malignancies | NCT02587598 | Solid Tumors | INCB053914 I-DAC (Intermed... Azacitidine Ruxolitinib | 18 Years - | Incyte Corporation | |
| The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients | NCT02648932 | Acute Myeloid L... Myelodysplastic... | Haplo-Cord Tran... Matched Unrelat... | 18 Years - | University of Chicago | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer | NCT02240537 | Acute Myelogeno... Multiple Myelom... Myelodysplastic... Smoldering Mult... | Sargramostim BB-MPI-03 Montanide | 18 Years - | Benovus Bio, Inc. | |
| Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY | NCT02992860 | Myelodysplastic... Acute Myeloid L... | JNJ-56022473 Bone marrow ana... Flow cytometry ... Central biobank... Histopathology ... Cytogenetic ana... Serum chemistry Automated CBC Pregnancy Test | 18 Years - | GWT-TUD GmbH | |
| Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics | NCT05534620 | Acute Myeloid L... Myelodysplastic... Allogeneic Hema... | Treosulfan Fludarabine | 18 Years - 80 Years | medac GmbH | |
| A Study of Single and Multiple Dose Administration of LP-001 in Healthy Subjects | NCT06294275 | Myelodysplastic... | LP-001 Dose 1 (... LP-001 Dose 2 (... LP-001 Dose 3 (... LP-001 Dose 4 (... LP-001 Dose 5 (... LP-001 Dose 6 (... Placebo (Single... LP-001 Dose 7 (... LP-001 Dose 8 (... Placebo (Multip... | 18 Years - 50 Years | Longbio Pharma | |
| Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | NCT00255346 | Acute Myeloid L... Myelodysplastic... Agnogenic Myelo... Myelofibrosis Hypereosinophil... Polycythemia Ve... Mastocytosis Leukemia, Myelo... | Dasatinib (BMS-... | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
